Program

 

PRE-CONFERENCE - Wednesday, 18 September 

 
 
Logo_Liverpool_Course

ZETA Meeting room of the Radisson Blu Hotel "Lietuva"

Free registration for all registered participants of the 5th CEE Meeting 

 15:30Registration and sandwich buffet
 
 16:00

Welcome and Introduction
Saye Khoo, PhD, University of Liverpool, United Kingdom
Saulius Caplinskas, MD, PhD, ULAC, Lithuania

 
 16:05Khoo, Saye 2016 120x160Introductory lecture + questions
Saye Khoo, MD, PhD, University of Liverpool, United Kingdom
 
  16:35Mini Lecture - HIV/HCV coinfection
Fiona Marra, University of Liverpool, United Kingdom
 
 17:05Coffee break
 
 17:25

Milosz Parczewski, MD, PhD

Case 1 Multimorbidity + questions and discussion
Milosz Parczewski, MD, PhD, Pomeranian Medical University, Poland

 17:55Anca Streinu-Cercel, MD, PhDCase 2 Woman with HBV/HCV coinfection + questions and discussion

Anca Streinu-Cercel, MD, PhD, Carol Davila University of Medicine and Pharmacy, Romania

 
  18:25

Ales Chrdle photo (002)Case 3 Chemsex + questions and discussion
Aleš Chrdle, MD, České Budějovice Hospital, Czech Republic

 18:55Closing remarks
  19:00              DINNER FOR ALL PARTICIPANTS 
   The Liverpool Course is supported by an independent educational grant from ViiV Healthcare. ViiV Healthcare was not involved in the development of content or selection of faculty for this educational activity.
 

 

MAIN PROGRAM

Day 1 - Thursday, 19 September 2019

 
 08:45 Opening of the Workshop 
 Session 1: Epidemiology of HIV and Hepatitis in the CEE Countries and Access to Care
 
 09:00Epidemiology of Viral Hepatitis Infection and Treatment in Europe
Speaker to be confirmed
 
 9:30

Epidemiology of HIV Infection and Treatment in Europe
Teymur Noori, ECDC, Stockholm, Sweden

 
 10:00Where We Are in Terms of Providing Access and Where We Should Go
Speaker to be confirmed
 
    
 10:30 Coffee break and poster viewing 
    
 Session 2: Access to Care
 
 11:00 

EECA: Are We Lagging Behind?
Sergey Golovin, ITPCru, St. Petersburg, Russia

 
 11:10 

Access to Quality Assured  (WHO Prequalified) Generic Medicines in the Region
Liudmyla Maistat, Medicines Patent Pool, Geneva, Switzerland

 
 11:20

Access to Key Populations
Speaker to be confirmed

 
 11:30Round Table Discussion 
    
 Session 3: HIV and Hepatitis Co-Infection
 
 11:45

Management of HIV/HCV in Young Women
Vadim Rassokhin, MD, 1st St. Petersburg State Medical University "Acad. I.P. Pavlov", St. Petersburg, Russia

 
  Abstract-Driven Presentations 
 12:00 Door-to-door hepatitis C testing in three large cities of Georgia: A pilot study
Maia Butsashvili, Georgia
 #1
 12:10The prevalence of mutations of the Hepatitis C virus, associated with drug resistance to inhibitors of protein NS5A among patients of the republic of Belarus
Elena Gasich, Belarus
 #2
 12:20Discussion 
    
 12:30Group Picture and Lunch 
    
 13:30Industry-Sponsored Symposium 
    
 Session 4: PrEP
 
 14:30

PrEP and STI Testing in CEE: What are the Barriers, What Works?
Milosz Parczewski, MD, PhD, Pomeranian Medical University, Sczecin, Poland

 
  Abstract-Driven Presentations 
 15:00Persistence on HIV pre-exposure prophylaxis medication: A challenge in pre-exposure prophylaxis (PrEP) program in Georgia
Ekaterina Karkashadze, Georgia
 #3
 15:10Virological efficacy of first-line regimens, resistance profile and factors influencing adherence to ART in clinical practice in Ukraine
Tetiana Kyrychenko, Ukraine
 #4
 15:20Discussion 
 15:30 Coffee Break and Poster Viewing 
    
 16:00Industry-Sponsored Symposium 
    
 Session 5: Linkage to Care and Management of Treatment Failure in HIV
 
 17:00

Switching to Second-Line HIV Therapy
Pavel Khaykin, MD, MainFachArzt, Frankfurt, Germany

 
 17:30

Raben, DortheIntegrated Testing for HIV, Hepatitis, and STIs
Dorthe Raben, MSc, CHIP, Copenhagen, Denmark

 
 18:00Discussion 
    
 18:15End of Day 1
Welcome Reception and Poster Viewing
 
 19:30 Group Dinner
 
    
 

Day 2 - Friday, 20 September 2019

 
    
 Session 6: HIV and Tuberculosis Co-Infection
 
 9:00Management of TB and HIV Infection
Daria Podlekareva, MD 
University of Copenhagen, Copenhagen, Denmark
 
 9:30

The Challenging TB Case: Clinical, Virological, and Pharmacological Considerations
Jonathan Schapiro, MD, Sheba Medical Centre, Tel Aviv, Israel

 
 9:50 Discussion 
  

Abstract-Driven Presentations

 
 10:00 Epidemiology of HIV in the Baltic countries (Estonia, Latvia, Lithuania)
Saulius Čaplinskas, Lithuania
 #5
 10:10 Uptake and outcomes of dolutegravir based antiretroviral therapy in Georgia
Nino Rukhadze, Georgia
 #6
 10:20 The new tendencies in HIV and HCV epidemics in central region of Ukraine
Tetiana Koval, Ukraine
 #7
    
 10:30Coffee Break and Poster Viewing 
    
 Session 7: Abstract-Driven Presentations
 
 11:00 Management of Hepatitis C in primary healthcare in the country of Georgia
Akaki Abutidze, Georgia
 #8
 11:10 HCV prevalence and associated factors among people who inject drugs (PWID): Baseline results of Georgian PWID cohort study
Ketevan Shermadini, Georgia
 #9
 11:20 Diversity of HIV-1 subtypes in Russia 2009-2019
Konstantin Gromov, Russia
 #10
 11:30 Outcomes for hepatitis B vaccination among HIV-infected adults in Georgia
Shorena Dvali, Georgia
 #11
 11:40 Epidemiology of Hepatitis B viral infection in the republic of Belarus
Viktar Mitsura< Belarus
 #12
 11:50 Implementation of the State Program on elimination of viral hepatitis C in Ukraine: achievements and challenges
Kristyna Pronyuk, Ukraine
 #13
 12:00 High level of integrase strand transfer inhibitors drug resistance mutations in INSTIs failed HIV-1 CRF06_cpx infected patients in Estonia
Merit Pauskar
 #14
    
 12:00 Lunch 
    
 Session 8: Hot Topics in HIV and Hepatitis
 
 13:00Schwarze-Zander, CarolynneVaccinations for HIV patients: Which Vaccinations When and How?
Carolynne Schwarze-Zander, PhD, University of Bonn, Bonn, Germany
 
 13:25

Treatment of Hepatitis B: What are the Remaining Challenges?
Olga Golubovska, MD, PhD, Bogomolets National Medical University, Kyiv, Ukraine

 
 13:50

Ligita JančorienėHIV/HCV Co-Infection: Influence on Risk for Cancer and Cardiovascular Events, and Impact of Successful HCV Cure 
Ligita Jancoriene, MD, PhD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania

 
 14:15 

 Jürgen Rockstroh, MDThe Acute HCV Epidemic in MSM: What Did We Learn So Far?
Juergen Rockstroh, MD, University of Bonn, Bonn, Germany

 
    
 14:40 End of Conference